188 research outputs found
"La Tutela del Interés legítimo en el Ordenamiento Italiano: Nuevas Perspectivas para el Ciudadano”
No full text1. La responsabilidad por lesión del interés legítimo: las raíces del problema.—2. Las razones
de la nueva posición jurisprudencial.—3. La reconstrucción jurídica hecha por el Pleno de la
Sala Contencioso-Administrativa de la Corte de Casación y la jurisprudencia posterior.—4. El
interés legítimo como instrumento de control de la actividad administrativa
Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable: implications for radiochemotherapy.
No full textMitomycin C (Me) is used as therapy against solid tumors, also combined with other chemotherapeutic agents or radiotherapy. It may cause acute, subacute, or chronic anemia capable of modifying the results of chemo- and radiotherapy. Erythropoietin may be lowered by cancer itself or because of chemoradiotherapy. There are few studies investigating the relationship between erythropoietin and chronic anemia. We prospectively analyzed the chronic anemia and erythropoietin in 38 patients with solid cancer. Patients were 40 to 82 years of age. MC was randomly given every 3 weeks as a single drug at 10 or 20 mg/m2• When myelotoxicity occurred the next therapy cycle was delayed until recovery. RBCindices, hemolysis, erythropoietin, liver and kidney function were studied. MCcycles were 136 (3.6 ± 1.4 per pt), 32 being delayed because of myelotoxicity. Hematocrit, hemoglobin and RBC were inversely related to the cumulative dose (r = 0.70 to 0.86; p 0.03 to 0.01) of MC. Other tests remained stable. Anemia occurred almost twofold earlier in the 20 mg/m2 group (p=0.049). Basal erythropoietin, already lower than in age and sex watched 81 non cancerous subjects (p<O.OOI),decreased during MCtherapy (p<O.OI). For each given MC mg/m2 a 0.0372 Hb mg/dl reduction occurred. Chronic anemia due to MCis accompanied by erythropoietin reduction. These results can help in designing chemoradiotherapy. © E.S.I.F.T. srl- Rrenze
La disciplina delle aree tutelate per legge
No full textIl contributo esamina la categoria dei c.d. beni paesaggistici ex lege alla luce delle regole e dei principi ricavabili dal Codice dei beni culturali e del paesaggio (d.lgs. 22 gennaio 2004, n. 42) e dalla Convenzione europea del paesaggio (ratificata con l. 9 gennaio 2006, n. 14) per poi approfondire la disciplina dettata con riferimento a tali beni dal Piano di indirizzo territoriale con valenza di piano paesaggistico approvato dalla Regione Toscana con D.C.R. 27 marzo 2015, n. 33
Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma.
No full textBetween February 1991 and July 1992, 79 previously untreated patients with metastatic colorectal carcinoma were enrolled in a phase II study of combined 5-fluorouracil (5-FU) and l-folinic acid (FA). 5-FU 370 mg/m2/day was administered for 5 consecutive days as an intravenous (i.v.) bolus injection preceded by l-FA 100 mg/m2/day with the same administration modality. Treatment was given every 4 weeks until progression. 79 patients were evaluable for toxicity and 64 for response. 2 patients (3\%) achieved a complete remission and 8 (12.5\%) a partial remission, 33 (52\%) had stable disease and 21 patients (33\%) had progressive disease. Median duration of remission was 32.5 weeks and median survival for all evaluable patients was 64.5 weeks. Substantial to severe side-effects occurred in 39\% of patients. Dose-limiting toxicity (grade 3-4) was mainly diarrhoea (18\%) and mucositis (15\%). Nausea/vomiting, cutaneous toxicity, leucopenia, alopecia and conjunctivitis of grade 3-4 occurred respectively in 6, 4, 2.5, 1 and 1\% of cases. Toxicity appeared to be substantially similar to that characteristic of combined 5-FU and the chiral mixture of d,l-FA. Efficacy was within the range of that observed with the 5-FU/d,l-FA combination, although at the lower level
- …
